Search
May 20, 2024
ATS2024: Endeavor BioMedicines' Hedgehog inhibitor showed improvements in lung function, capacity, and other measures at 12-weeks in IPF
John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than...
Apr 26, 2024
John Hood on Endeavor's $132.5M series C and hedgehog inhibition for IPF
He describes the phase 2 data in IPF that Endeavor unveiled in January and enabled this week's raise.
.png){kind=logo}
